ATHE
NASDAQAlterity Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks53-72%
2025-12-142026-06-07
Mix3990d
- SEC Filings23(59%)
- Other8(21%)
- Insider6(15%)
- Leadership2(5%)
Latest news
25 items- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) were delivered at three medical conferences showcasing Alterity's novel imaging and biomarker approach, promisi
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) – – Findings support QSM as an objective imaging biomarker to enable earlier diagnosis and assess iron-modulating therapies in MSA, including Alterity's lead candidate ATH434 – MELBOURNE, Australia and SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335)Type: Oral PresentationPresenter: Pau
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate UpdateHighlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA meeting mid-year 2026Late breaking platform presentation at American Academy of Neurology annual meeting demonstrated consistent evidence of efficacy and reinforces ATH434's clinical profileStrengthened clinical leadership with appointment of Dr. Daniel Claassen as Chief Medical AdvisorEnhanced Board of Directors with appointment of Ms. Ann Cunningham, bringing extensive global commercial and neurodegenerative disease expertiseHosted a virtual KOL event featuring leading expe
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- INSIDERSEC Form 3 filed by new insider Cunningham Ann Michelle3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing in parallel – – End-of-Phase 2 meeting with FDA remains on track for mid-2026 – MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I - - Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators - MELBOURNE, Australia and SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of new data analyses from the Phase 2 trial of ATH43
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of DirectorsMELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
ATHE FAQ
6 questionsWhat does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.Where does ATHE stock trade?
Alterity Therapeutics Limited (ATHE) is listed on NASDAQ.What sector and industry is ATHE in?
Alterity Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATHE?
Alterity Therapeutics Limited has had 3 recent analyst actions on file. The most recent action was from The Benchmark Company: Hold on 2025-02-03. Recent price targets range from $400.00 to $800.00.What companies are similar to ATHE?
Notable peers in the same industry include ACRS (Aclaris Therapeutics Inc.), RUBY (Rubius Therapeutics Inc.), ONTX (Onconova Therapeutics Inc.). Compare ATHE side-by-side with any of them on Quantisnow.How can I track ATHE on Quantisnow?
Quantisnow aggregates Alterity Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHE to receive live email and push alerts on every new disclosure.